{"id":51916,"date":"2022-12-13T15:02:17","date_gmt":"2022-12-13T14:02:17","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/"},"modified":"2022-12-13T15:02:17","modified_gmt":"2022-12-13T14:02:17","slug":"trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/","title":{"rendered":"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation"},"content":{"rendered":"
\n

CHAPEL HILL, N.C. & BIRMINGHAM, Ala.–(BUSINESS WIRE)–Trialbee<\/a>, the leader in data and technology-based patient recruitment and enrollment for clinical trials, today announced a partnership with Acclinate<\/a>, whose NOWINCLUDED\u2122 community accesses and engages diverse populations on health-related issues. The partnership is aimed at achieving greater equity in clinical trial participation by leveraging the NOWINCLUDED\u2122 community through Trialbee Honey\u2122 Omnichannel.\n<\/p>\n

<\/a><\/p>\n

\nTrialbee will work with Acclinate to access and engage communities of color, encouraging disease and trial awareness within designated geographies. NOWINCLUDED\u2122 will grow indication-specific communities and introduce trial opportunities to members. The partnership will leverage Acclinate’s e-DICT\u2122 platform, which assigns a proprietary Participant Probability Index (PPI) score to assess community members’ willingness to participate in clinical research. Interested members are then educated, pre-qualified and referred to research sites through Trialbee Honey\u2122 Omnichannel. Sponsors and contract research organizations (CROs) that aim to improve representation in their clinical trial enrollment activities can measure success of community engagement and enrollment performance.\n<\/p>\n

\nThe partnership addresses a major challenge in clinical research: engaging and enrolling diverse patient populations into clinical trials. Racial and ethnic minorities comprise 42% of the U.S. population but only account for 2% to 16% of clinical trial participants.<\/a>\n<\/p>\n

\n\u201cMerging the patient journey from complementary engagement channels onto a single platform lets us take a holistic approach to solving today\u2019s challenges with patient recruitment and enrollment,\u201d says Matt Walz, CEO of Trialbee. \u201cAcclinate\u2019s approach with NOWINCLUDED\u2122 is innovative and focuses on overcoming well documented issues around trust within communities of color. When combined with the power of our Honey platform, we\u2019re much better positioned to achieve more equitable clinical research.\u201d\n<\/p>\n

\nLupus has been chosen as the pilot indication to demonstrate the power of the partnership. It is a complex disease that takes an average of five years following the onset of symptoms to diagnose<\/a>, and because of its unique patient population characteristics, it presents recruitment and diversity challenges for clinical trials. The disease predominantly affects women, and it disproportionately affects women who identify as African American, Hispanic, Asian, and Native American, which makes their access to research trials critical.\n<\/p>\n

\n\u201cOur data and use cases show that sustained, affective engagement with diverse communities prior to the opportunity to take part in a clinical trial yields significantly higher enrollment and retention rates,\u201d says Dr. Del Smith, CEO of Acclinate. \u201cThe partnership with Trialbee represents an innovative, best-in-class integration of our NOWINCLUDED\u2122 and e-DICT engagement platform with Trialbee\u2019s Honey\u2122 patient recruitment platform and will go a long way toward achieving these goals.\u201d\n<\/p>\n

\nBoth companies competed at the DPHARM\u00ae Idol Disrupt competition during the 12th annual DPHARM\u00ae: Disruptive Innovations to Modernize Clinical Research conference in Boston in September.\n<\/p>\n

\n\u201cWe had mutual admiration as our models are disruptive on their own, but it was obvious our impact could be amplified by combining them,\u201d says Walz.\n<\/p>\n

\nResearch organizations interested in experiencing this solution can request a simulation here<\/a>.\n<\/p>\n

\nAbout Trialbee
\n
<\/b>Trialbee is the leading global data and technology platform for patient recruitment and enrollment in clinical trials. Trialbee Hive\u2122 operationalizes real world data (RWD) and applies data science to find patients globally. Trialbee Honey\u2122 simplifies the journey into clinical research for patients, reduces the burden of enrolling patients for sites and provides real-time, data-driven insights to sponsors and CROs so they can optimize enrollment timelines. Partnering with sponsors, CROs, and virtual\/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http:\/\/www.trialbee.com<\/a> or contact us at solutions@trialbee.com<\/a>.\n<\/p>\n

\nAbout Acclinate
\n
<\/b>Acclinate’s vision is health equity through inclusive research. We are a digital health company specializing in accessing and engaging communities of color so they can make informed decisions about clinical trial participation. Learn more at https:\/\/www.acclinate.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMatt McLoughlin
\n
Gregory FCA (for Trialbee)
\n
610.228.2123
\n
Matt@GregoryFCA.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CHAPEL HILL, N.C. & BIRMINGHAM, Ala.–(BUSINESS WIRE)–Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, today announced a partnership with Acclinate, whose NOWINCLUDED\u2122 community accesses and engages diverse populations on health-related issues. The partnership is aimed at achieving greater equity in clinical trial participation by leveraging the NOWINCLUDED\u2122 community through … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51916","6":"format-standard","7":"category-industry"},"yoast_head":"\nTrialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CHAPEL HILL, N.C. & BIRMINGHAM, Ala.–(BUSINESS WIRE)–Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, today announced a partnership with Acclinate, whose NOWINCLUDED\u2122 community accesses and engages diverse populations on health-related issues. The partnership is aimed at achieving greater equity in clinical trial participation by leveraging the NOWINCLUDED\u2122 community through ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-13T14:02:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221213005211\/en\/1662514\/21\/Trialbee-Logo_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation\",\"datePublished\":\"2022-12-13T14:02:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/\"},\"wordCount\":669,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005211\\\/en\\\/1662514\\\/21\\\/Trialbee-Logo_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/\",\"name\":\"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005211\\\/en\\\/1662514\\\/21\\\/Trialbee-Logo_%281%29.jpg\",\"datePublished\":\"2022-12-13T14:02:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005211\\\/en\\\/1662514\\\/21\\\/Trialbee-Logo_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221213005211\\\/en\\\/1662514\\\/21\\\/Trialbee-Logo_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/","og_locale":"en_US","og_type":"article","og_title":"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation - Pharma Trend","og_description":"CHAPEL HILL, N.C. & BIRMINGHAM, Ala.–(BUSINESS WIRE)–Trialbee, the leader in data and technology-based patient recruitment and enrollment for clinical trials, today announced a partnership with Acclinate, whose NOWINCLUDED\u2122 community accesses and engages diverse populations on health-related issues. The partnership is aimed at achieving greater equity in clinical trial participation by leveraging the NOWINCLUDED\u2122 community through ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-13T14:02:17+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221213005211\/en\/1662514\/21\/Trialbee-Logo_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation","datePublished":"2022-12-13T14:02:17+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/"},"wordCount":669,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221213005211\/en\/1662514\/21\/Trialbee-Logo_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/","url":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/","name":"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221213005211\/en\/1662514\/21\/Trialbee-Logo_%281%29.jpg","datePublished":"2022-12-13T14:02:17+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221213005211\/en\/1662514\/21\/Trialbee-Logo_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221213005211\/en\/1662514\/21\/Trialbee-Logo_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/trialbee-and-acclinate-partner-to-enhance-equitable-clinical-trial-participation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51916"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51916\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}